ESMO26: Oral cell cycle inhibitors place Cyclin E1 as new target in PROC
Two PROC candidates that act on Cyclin E1 were presented at ESMO 2026.
Comment & Opinion
Egypt reforms obsolete pharmaceutical pricing framework
Danish fast-track model inspires growth in national reimbursement rates
Global systems unprepared for rising threat of invasive fungal infections
CPHI 2026: Finding the right CDMO partner in an age of consolidation
Suspected plague outbreak in Russia: public health risk lower than Covid-19
CPHI 2026: Moderna builds on its COVID-era manufacturing lessons
EASD 2026: Tirzepatide outperforms semaglutide in real-world type 2 diabetes analysis
